RYTM News

The IPO market kicked off the fourth quarter with the wind at its back. IPO performance remained strong for yet another week as two companies raised a combined $651 million and generated double-digit returns. Following last week's pop from Roku (ROKU: +66% from IPO), another tech IPO,...read more

Rhythm Pharmaceuticals, which is developing peptide-based therapies to treat rare genetic obesity, raised $120 million by offering 7 million shares at $17, above the range of $14 to $16. It originally filed to offer 6.7 million shares. Rhythm Pharmaceuticals plans to list on the Nasdaq under the symbol RYTM. Morgan Stanley, BofA Merrill Lynch and Cowen & Company acted as lead...read more

Three deals are set to raise a combined $669 million in the coming week. Data center operator Switch (SWCH) is expected to raise $469 million in the largest tech IPO since Snap (SNAP). A peptide-based biotech and energy-focused SPAC also plan to price. Several deals will become able to launch this week, including a $750 million IPO...read more

Rhythm Pharmaceuticals, a clinical-stage biotech developing peptide-based therapies to treat genetic obesity, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Rhythm Pharmaceuticals would command a fully diluted market value of...read more